ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Voriconazole therapeutic drug monitoring and hepatotoxicity in critically ill patients: A nationwide multi-centre retrospective study

Wang, Taotao; Miao, Liyan; Shao, Hua; Wei, Xiaohua; Yan, Miao; Zuo, Xiaocong; Zhang, Jun; Hai, Xin; Fan, Guangjun; Wang, Wei; Hu, Linlin; Zhou, Jian; Zhao, Yichang; Xie, Yueliang; Wang, Jingjing; Guo, Sixun; Jin, Liu; Li, Hao; Liu, Hui; Wang, Quanfang; Chen, Jiaojiao; Li, Sihan; Dong, Yalin*南昌大学; 哈尔滨医科大学; 苏州大学; 西安交通大学; 1
International Journal of Antimicrobial Agents2022-11DOI: 10.1016/j.ijantimicag.2022.106692
5被引24阅读
引用收藏
分享

摘要

Objectives: To characterize trough concentrations (Cmin) of voriconazole and associated hepatotoxicity, and to determine predictors of hepatotoxicity and identify high-risk groups in critically ill patients.Methods: This was a nationwide, multi-centre, retrospective study. Cmin and hepatotoxicity were studied from 2015 to 2020 in 363 critically ill patients who received voriconazole treatment. Logistic regression and classification and regression tree (CART) models were used to identify high-risk patients.Results: Large interindividual variability was observed in initial voriconazole Cmin and concentrations ranged from 0.1 mg/L to 18.72 mg/L. Voriconazole-related grade >2 hepatotoxicity developed in 101 pa-tients, including 48 patients with grade >3 hepatotoxicity. The median time to hepatotoxicity was 3 days (range 1-24 days), and 83.2% of cases of hepatotoxicity occurred within 7 days of voriconazole initiation. Voriconazole Cmin was significantly associated with hepatotoxicity. The CART model showed that signif-icant predictors of grade >2 hepatotoxicity were Cmin > 3.42 mg/L, concomitant use of trimethoprim-sulfamethoxazole or tigecycline, and septic shock. The model predicted that the incidence of grade >2 hepatotoxicity among these high-risk patients was 48.3-63.4%. Significant predictors of grade >3 hepato-toxicity were Cmin > 6.87 mg/L, concomitant use of at least three hepatotoxic drugs, and septic shock; the predictive incidence among these high-risk patients was 22.7-36.8%. Conclusion: Higher voriconazole Cmin, septic shock and concomitant use of hepatotoxic drugs were the strongest predictors of hepatotoxicity. Plasma concentrations of voriconazole should be monitored early (as soon as steady state is achieved) to avoid hepatotoxicity.

学科与关键词

关键词
VoriconazoleHepatotoxicityTrough concentrationsCritically ill patients
相关
加载中…
  • Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases
    Shen, Kunlu; Gu, Yu; Wang, Yu; Lu, Yajie; Ni, Yueyan; Zhong, Huanhiuan; Shi, Yi; Su, Xin*Therapeutic Advances in Drug Safety, 2022, 13.被引 7
  • Combined Effect of CYP2C19 Genetic Polymorphisms and C-Reactive Protein on Voriconazole Exposure and Dosing in Immunocompromised Children
    Chen, Juan; Wu, Ying; He, Yuelin; Feng, Xiaoqin; Ren, Yuqiong; Liu, Shiting*Frontiers in Pediatrics, 2022, 10: 846411.被引 7
  • Invasive Pulmonary Aspergillosis in Acute-on-Chronic Liver Failure Patients: Short-Term Outcomes and Antifungal Options
    Chen, Danli; Qian, Zhiping; Su, Haibin; Meng, Zhongji; Lv, Jun; Huang, Yan; Gao, Yanhang; Liu, Jingyuan; Zhao, Caiyan; Gao, Hongbo; Chen, Yu; Xia, Jie; Peng, Liang; Han, Tao; Li, Hai; Zheng, Xin; Wang, Xianbo*; Lu, Xiaobo; Shi, Yu*; Hu, Jinhua; Chen, Jinjun*Infectious Diseases and Therapy, 2021, 10(4): 2525-2538.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
International Journal of Antimicrobial Agents
发表日期
2022-11
卷期
第 60 卷, 第 5-6 期
页码
106692
DOI
10.1016/j.ijantimicag.2022.106692
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
Key Research and Development Programme of Shaanxi; National Natural Science Foundation of China; [2019ZDLSF01-05]; [2020SF- 064]; [82070549]

作者

  • W

    Wang, Taotao (第一作者)

    1 · xi an jiao tong univ

  • M

    Miao, Liyan

    1 · soochow univ

查看全部 23 位作者收起作者
  • S

    Shao, Hua

    southeast univ

  • W

    Wei, Xiaohua

    1 · nanchang univ

  • Y

    Yan, Miao

    2

  • Z

    Zuo, Xiaocong

  • Z

    Zhang, Jun

    1 · kunming med univ

  • H

    Hai, Xin

    1 · harbin med univ

  • F

    Fan, Guangjun

    2 · dalian med univ

  • W

    Wang, Wei

    1 · soochow univ

  • H

    Hu, Linlin

    southeast univ

  • Z

    Zhou, Jian

    1 · nanchang univ

  • Z

    Zhao, Yichang

    2

  • X

    Xie, Yueliang

  • W

    Wang, Jingjing

    1 · kunming med univ

  • G

    Guo, Sixun

    1 · harbin med univ

  • J

    Jin, Liu

    2 · dalian med univ

  • L

    Li, Hao

    1 · xi an jiao tong univ

  • L

    Liu, Hui

    1 · xi an jiao tong univ

  • W

    Wang, Quanfang

    1 · xi an jiao tong univ

  • C

    Chen, Jiaojiao

    1 · xi an jiao tong univ

  • L

    Li, Sihan

    1 · xi an jiao tong univ

  • D

    Dong, Yalin (通讯)

    1 · xi an jiao tong univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417